When 90% Isn't an A+: Elevance's Cost Crunch and Carelon's Cushion

Elevance Health (ELV) is experiencing significant margin compression due to rising medical costs and increased utilization, evidenced by a projected 2025 benefit expense ratio near 90%, up from 88.5% in 2024, prompting a reduced outlook. While this pressure is industry-wide, impacting peers like UnitedHealth and Centene, ELV anticipates its robust commercial segment growth, with a 9.7% rise in individual memberships in 1H 2025, and strong performance from its Carelon operations, projected to climb nearly 30% in 2025, will partially offset these headwinds. Despite these internal strengths, ELV shares have underperformed, declining 20.7% year-to-date, reflecting investor concern over the challenging cost environment and a Zacks Strong Sell rating.

Analysis

Elevance Health (ELV) is facing significant margin compression from systemic industry headwinds, primarily rising medical cost trends and increased utilization. This is quantified by its second-quarter benefit expense ratio reaching 88.9%, a 260 basis point year-over-year increase, and a full-year 2025 projection near 90%. This pressure, which has contributed to a 20.7% year-to-date decline in its share price and a consensus estimate for a 7.4% earnings decline in 2025, is also impacting peers like UnitedHealth and Centene, whose medical cost ratios have deteriorated by 430 and 540 basis points, respectively. However, Elevance possesses two key offsets that could provide a partial cushion. The first is its high-growth Carelon segment, where revenues are projected to climb nearly 30% in 2025, driven by a 60% surge in its services arm. The second is continued strength in its higher-margin commercial business, which saw individual memberships rise 9.7% in the first half of 2025. Despite these internal growth drivers and a discounted forward P/E ratio of 9.19 versus the industry average of 14.57, the negative market sentiment is reinforced by a Zacks Rank #5 (Strong Sell).

Key Decisions for Investors

• Given the rising benefit expense ratio is the primary headwind, investors should closely monitor this metric in subsequent quarters for any signs of stabilization, as it is the key driver of margin compression and earnings pressure.
• The performance of the Carelon segment is critical to the investment thesis; therefore, scrutinize its revenue growth to ensure it meets the projected 30% target, as any deceleration would remove a key offset to the core business's weakness.
• Despite the stock's low valuation at a 9.19 forward P/E, the 'Strong Sell' rating and negative earnings outlook suggest a potential value trap, so it may be prudent to await a stabilization in medical cost trends or an improved company outlook before considering a long position.